Evidence map›Paper›PMID 25387095›Full record

Trial reportBone marrow transplantation2015

Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome.

X-D Mo, L-P Xu, X-H Zhang, D-H Liu, Y Wang, H Chen, C-H Yan, Y-H Chen, W Han, F-R Wang and 3 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

X-D MoPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
L-P XuPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
X-H ZhangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
D-H LiuPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Y WangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
H ChenPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
C-H YanPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Y-H ChenPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
W HanPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
F-R WangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
J-Z WangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
K-Y LiuPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
X-J Huang1] Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China [2] Peking-Tsinghua Center for Life Sciences, Beijing, China.
Peking University · CNPeking University People's Hospital · CNCenter for Life Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate the impact of occurrence of chronic GVHD (cGVHD) and its severity on transplantation outcomes in a consecutive cohort of AML and myelodysplastic syndrome (MDS) patients who received unmanipulated haploidentical hematopoietic SCT (haplo-HSCT; n=324). The cumulative incidence of relapse was significantly decreased in patients with cGVHD compared with the non-cGVHD group (1 year: 3.2% vs 11.9%, P=0.002; 3 years: 6.0% vs 16.3%, P=0.002), particularly in those with mild cGVHD. The cumulative incidence of non-relapse mortality was comparable between patients with and without cGVHD. The probabilities of disease-free survival (DFS) were significantly better in patients with cGVHD than in those in the non-cGVHD group (1 year: 90.5% vs 78.5%, P=0.002; 3 years: 86.5% vs 71.5%, P<0.001), particularly in those with mild or moderate cGVHD; however, no significant impact of severe cGVHD on DFS was seen. Our findings highlight the close relationship between cGVHD and the immune-mediated GVL effect in patients with AML and MDS receiving unmanipulated haplo-HSCT; however, only mild or moderate cGVHD was associated with a lower risk of relapse translating into improved DFS.

Indexed as

Graft vs Host DiseaseGraft vs Leukemia EffectHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMyelodysplastic SyndromesAdolescentAdultAllograftsChildChild, PreschoolChronic DiseaseDisease-Free SurvivalFemaleHumansIncidenceMale

Identifiers

PMID25387095
OpenAlexW2000831487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.